Spectrum Pharmaceutecals Inc (SPPI)

[Ville]

Looking at the phase 2 data of Rolontis (n=36) and the phase 3 data of the first study i would like to see the superiority value for the phase 3 study.

With those values and n = 406 i think there could still be a chance to have met superiority in the first phase 3 study. They maybe just hit superiotrity and hold back this information til the second study hits, because they need to have superiority in both studies to have it in the label. Just a speculation.